

10/568466
IAP20 REG'D IN PTO 14 FEB 2006

"Express Mail" mailing label number <u>EV 393128433</u>	
Date of Deposit <u>FEB. 14, 2006</u>	
I hereby certify that this paper or fee is being deposited with the United States Postal Service "Express Mail Post Office to Addressee" service under 37 C.F.R. 1.10 on the date indicated above and is addressed to the Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.	
QUEEN THOMAS	<i>Queen Thomas</i>
Printed Name	Signature

PATENT APPLICATION
IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

First Applicant: ALLEN, Albert J.

International

Serial No.: PCT/US2004/025593

International

Application Date: August 25, 2004

US Nat'l Entry

Date (if applicable):

Group Art Unit:

Examiners:

Conf No.:

For: TREATMENT OF PERVASIVE
DEVELOPMENTAL DISORDERS WITH
NOREPINEPHRINE REUPTAKE INHIBITORS

Docket No.: X-16410

INFORMATION DISCLOSURE STATEMENT

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

As a means of complying with the duty of disclosure, Applicants submit an "Information Disclosure Citation In An Application" on a Form PTO-1449 (modified) and provide a copy of each of the listed documents for consideration by the Examiner.

Since this Statement is being filed in accordance with 37 C.F.R. 1.97(b), Applicants submit that no additional fee is required.

10/568466

IAP20 Rec'd PCT/PTO 14 FEB 2006

-2-

Applicants request consideration of this information.

Respectfully submitted,

Charles E. Cohen

Charles E. Cohen, Ph.D.
Attorney for Applicants
Registration No. 34,565
Phone: 317-433-4983

Eli Lilly and Company
Patent Division
P.O. Box 6288
Indianapolis, Indiana 46206-6288

February 7, 2006

10/1568466
 International Serial No
 PCT/US2004/025593

FORM PTO 1449 (modified) INFORMATION DISCLOSURE CITATION IN AN APPLICATION	Atty. Docket No. X-16410	International Serial No PCT/US2004/025593
	First Applicant ALLEN, Albert John	
	Filing Date US Nat'l Entry (if applicable)	Group

U.S. PATENT DOCUMENTS

Examiner Initials*	Cite No. ¹	Document Number Number-Kind Code ² (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Pages or Relevant Figures Appear
	AA	US 5 281 624 A	01-25-1994		

FOREIGN PATENT DOCUMENTS

Examiner Initials*	Cite No. ¹	Foreign Patent Document Country Code ³ -Number ⁴ - Kind Code ⁵ (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ⁶
	BA	WO 02/070457	09-12-2002			
	BB	EP 0 721 777 A	07-17-1996			
	BC	WO 01/62236 A	08-30-2001			
	BD	WO 02/053140 A	07-11-2002			
	BE	WO 01/01973 A	01-11-2001			
	BF	WO 02/102297 A	12-27-2002			
	BG					
	BH					

NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s) publisher, city and/or country where published.	T ⁶
	CA	International Preliminary Report on Patentability	
	CB	International Search Report	
	CC	GRAUL A I, "Annual Update 2003: Drugs for Psychiatric Disorders and Substance Abuse" <i>Drugs of the Future</i> (2003) Vol. 28, No. 11, pgs. 1103-1144	
	CD	TAYLOR E., et al., "European clinical guidelines for hyperkinetic disorder – first upgrade", <i>European Child and Adolescent Psychiatry</i> , (2004) Vol. 13, Suppl. 1, pgs. 1/7-1/30	
	CE	ANONYMOUS, "Medication Reference", <i>Internet Article –Autism Center</i> , August 2003	
	CF	GORDON C T, et al., <i>American Journal of Psychiatry</i> , (1992) Vol. 149, No. 3, pgs. 363-366	

FORM PTO 1449 (modified)		Atty. Docket No. X-16410	International Serial No. PCT/US2004/025593
INFORMATION DISCLOSURE CITATION IN AN APPLICATION		First Applicant ALLEN, Albert John	
		Filing Date US Nat'l Entry (if applicable)	Group
NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s) publisher, city and/or country where published.	T ⁶

	CG	GEHLERT D R., et al., "(R)-Thionisoxetine, A Potent and Selective Inhibitor of Central and Peripheral Norepinephrine Uptake", <i>Life Sciences</i> , (1995) Vol. 56, No. 22, pgs 1915-1920	
	CH	GEHLERT D R., "Localization of rat brain binding sites for tritiated tomoxetine, an enantiomerically pure ligand for norepinephrine reuptake sites" <i>Neuroscience Letters</i> , (1993) Vol. 157, No. 2, pages 203-206	
	CI	DSM-IV, Fourth Edition, "Disorders Usually First Diagnosed in Infancy, Childhood, or Adolescence", pgs. 37-39; 65-78	
	CJ	DSM-IV-TR, Fourth Edition, "Disorders Usually First Diagnosed in Infancy, Childhood, or Adolescence", pgs. 39-41; 69-84	
	CK	DSM-III-R, Third Edition, "Disorders Usually First Evident in Infancy, Childhood, or Adolescence", pgs. 27-28; 33-49	
	CL	Medication Reference Tables, "The latest data on medications for PDD symptoms", (2005) pgs. 1-5	
	CM	WONG D T, et al., "A New Inhibitor of Norepinephrine Uptake Devoid of Affinity for Receptors in Rat Brain" <i>The Journal of Pharmacology and Experimental Therapeutics</i> , (1982) Vol. 222, No. 1, pgs. 61-65	
	CN	Cusak B, et al., "Binding of antidepressants to human brain receptors: focus on newer generation compounds" <i>Psychopharmacology</i> , (1994) Vol. 114, pgs. 559-565	
	CO	Results of an Atomoxetine Pilot Study in Children with Autism Spectrum Disorders, pgs. 1-14	
	CP		

Examiner Signature	Date Considered
-----------------------	-----------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached. Burden Hours Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case.

Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.